Biochemical Markers of Diabetic Kidney Injury: A Pharmacological Perspective on Early Intervention
Keywords:
Diabetic kidney injury; Biochemical markers; Early diagnosis; Pharmacological intervention; NephroprotectionAbstract
Diabetic kidney injury represented a major contributor to chronic kidney disease progression and was driven by early biochemical and molecular disturbances that preceded overt functional decline. Conventional diagnostic markers often detected renal damage at advanced stages, limiting opportunities for timely therapeutic intervention. Emerging biochemical markers offered enhanced sensitivity for early detection and provided a potential framework for biomarker-guided pharmacological nephroprotection. This study aimed to synthesize clinician perspectives on biochemical markers associated with early diabetic kidney injury and to evaluate the perceived role of biomarker-guided pharmacological strategies in early renal protection. A cross-sectional, questionnaire-based observational study was conducted among 200 healthcare professionals, including nephrologists, endocrinologists, internal medicine physicians, and clinical pharmacologists. A structured, validated questionnaire assessed awareness of biochemical markers, clinical utilization patterns, and the influence of early biomarker changes on pharmacological decision-making. Descriptive and selective inferential statistical analyses were performed. Respondents demonstrated strong agreement regarding the diagnostic value of emerging biomarkers and routine biochemical monitoring for early renal injury detection. Elevated mean perception scores indicated high clinician confidence in biomarker-based approaches. Early biochemical changes were consistently perceived to influence pharmacological intervention, disease progression control, and patient outcomes. Inferential analyses revealed uniform perceptions across medical specializations and knowledge levels, suggesting consensus-driven clinical practice. The findings supported a unified biochemical–pharmacological framework for early diabetic kidney injury management. Integration of biochemical markers into routine clinical pathways was perceived to enhance early diagnosis, guide timely pharmacological intervention, and promote sustained renal preservation within preventive nephrology paradigms.
Downloads
References
Tain YL, Chan SH, Chan JY. Biochemical basis for pharmacological intervention as a reprogramming strategy against hypertension and kidney disease of developmental origin. Biochemical Pharmacology. 2018 Jul 1;153:82-90.
Pavlakou P, Liakopoulos V, Eleftheriadis T, Mitsis M, Dounousi E. Oxidative stress and acute kidney injury in critical illness: pathophysiologic mechanisms—biomarkers—interventions, and future perspectives. Oxidative medicine and cellular longevity. 2017;2017(1):6193694.
Jung CY, Yoo TH. Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease. Diabetes and metabolism journal. 2022 Mar 24;46(2):181-97.
Thakur V, Chattopadhyay M. Early urinary markers for diabetic and other kidney diseases. Current drug targets. 2018 Jun 1;19(7):825-31.
Jha R, Lopez-Trevino S, Kankanamalage HR, Jha JC. Diabetes and renal complications: an overview on pathophysiology, biomarkers and therapeutic interventions. Biomedicines. 2024 May 15;12(5):1098.
Tofte N, Lindhardt M, Adamova K, Bakker SJ, Beige J, Beulens JW, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. The lancet Diabetes and endocrinology. 2020 Apr 1;8(4):301-12.
Liu H, Feng J, Tang L. Early renal structural changes and potential biomarkers in diabetic nephropathy. Frontiers in physiology. 2022 Nov 8;13:1020443.
Gembillo G, Ingrasciotta Y, Crisafulli S, Luxi N, Siligato R, Santoro D, Trifirò G. Kidney disease in diabetic patients: from pathophysiology to pharmacological aspects with a focus on therapeutic inertia. International journal of molecular sciences. 2021 May 1;22(9):4824.
Nageeta FN, Waqar F, Allahi I, Murtaza F, Nasir M, Danesh FN, Irshad B, Kumar R, Tayyab A, Khan MS, Kumar S. Precision medicine approaches to diabetic kidney disease: Personalized interventions on the horizon. Cureus. 2023 Sep 19;15(9).
Kumar M, Dev S, Khalid MU, Siddenthi SM, Noman M, John C, Akubuiro C, Haider A, Rani R, Kashif M, Varrassi G. The bidirectional link between diabetes and kidney disease: mechanisms and management. Cureus. 2023 Sep 20;15(9):e45615.
Dubin RF, Rhee EP. Proteomics and metabolomics in kidney disease, including insights into etiology, treatment, and prevention. Clinical Journal of the American Society of Nephrology. 2020 Mar 1;15(3):404-11.
Pichler R, Afkarian M, Dieter BP, Tuttle KR. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. American Journal of Physiology-Renal Physiology. 2017 Apr 1;312(4):F716-31.
Kashani K, Cheungpasitporn W, Ronco C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption. Clinical Chemistry and Laboratory Medicine (CCLM). 2017 Jul 26;55(8):1074-89.
Gameiro J, Fonseca JA, Outerelo C, Lopes JA. Acute kidney injury: from diagnosis to prevention and treatment strategies. Journal of clinical medicine. 2020 Jun 2;9(6):1704.
Campion CG, Sanchez-Ferras O, Batchu SN. Potential role of serum and urinary biomarkers in diagnosis and prognosis of diabetic nephropathy. Canadian journal of kidney health and disease. 2017 May 19;4:2054358117705371.
Cao Q, Chen XM, Huang C, Pollock CA. MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: an update. FASEB BioAdvances. 2019 Jun;1(6):375-88.
Ibrahim RK, Ghudhaib KK, Allawi AA. Early prediction of nephropathy in Iraqi patient with diabetes type II by evaluating some relevant biochemical factors. Baghdad Science Journal. 2024 May 1;21(5):1549-.
Zhong J, Yang HC, Fogo AB. A perspective on chronic kidney disease progression. American Journal of Physiology-Renal Physiology. 2017 Mar 1;312(3):F375-84.
Heerspink HJ, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019 Jul;62(7):1154-66.
Chen S, Li B, Chen L, Jiang H. Uncovering the mechanism of resveratrol in the treatment of diabetic kidney disease based on network pharmacology, molecular docking, and experimental validation. Journal of Translational Medicine. 2023 Jun 12;21(1):380.
Pontillo C, Mischak H. Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease. Clinical kidney journal. 2017 Apr 1;10(2):192-201.
Oshima M, Shimizu M, Yamanouchi M, Toyama T, Hara A, Furuichi K, Wada T. Trajectories of kidney function in diabetes: a clinicopathological update. Nature Reviews Nephrology. 2021 Nov;17(11):740-50.
Hickson LJ, Prata LG, Bobart SA, Evans TK, Giorgadze N, Hashmi SK, Herrmann SM, Jensen MD, Jia Q, Jordan KL, Kellogg TA. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019 Sep 1;47:446-56.
Lu Z, Zhong Y, Liu W, Xiang L, Deng Y. The efficacy and mechanism of Chinese herbal medicine on diabetic kidney disease. Journal of diabetes research. 2019;2019(1):2697672.
de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes care. 2022 Dec 1;45(12):3075-90.
ISSN 2307-1257
ISSN 2307-1265
